Research
Hormonal
Tirzepatide increases HOMA-β and decreases HOMA-IR in T2D patients.
Tirzepatide may be effective in improving insulin sensitivity and β-cell function in T2D management.
StrongSupportsmedium confidence
In T2D patients, tirzepatide improved glycemic control, reduced insulin demand, increased HOMA-β, and decreased HOMA-IR.
Why this rating
The study includes clinical data from T2D patients.
Source
Tirzepatide improves pancreatic β-cell function in mice and patients with type 2 diabetes
Zhehui Li et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2026
DOI 10.64898/2026.02.13.704343
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →